United States-based PeproMene Bio Inc has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to study a novel chimeric antigen receptor (CAR) T cell therapy, PMB-101, it was reported on Wednesday.
PMB-101 is claimed to be the first CAR T cell therapy targeting the B cell-activating factor receptor (BAFF-R) on cancerous cells intended to treat refractory or relapsed B cell acute lymphoblastic leukaemia (r/r B-ALL).
An independent research and treatment centre for cancer, diabetes and other life-threatening diseases, City of Hope, has licensed intellectual property relating to PMB-101 under a Licensing and Collaboration agreement with PeproMene. It will also conduct the proposed first in-human, Phase one clinical trial.
The proposed trial is a single-centre, open-label trial to assess the safety and preliminary efficacy of BAFF-R-CAR T cells in cancer patients with r/r/ B-ALL who are ineligible for or have failed CD19-targeted immunotherapy in the United States. The product is a novel CAR T cell therapy which has indicated synergistic activity in CD-19 resistant or relapsed animal models in preclinical trials.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT